Clinical Trial Update: Low Dose Epcoritamab Plus GemOx in R/R DLBCL [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial is testing low-dose epcoritamab in combination with GemOx (gemcitabine and oxaliplatin) for relapsed/refractory diffuse large B-cell ly…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Diffuse Large B-cell Lymphoma

Drugs mentioned

• Epcoritamab (epcoritamab)
• Gemcitabine (Gemcitabine)
• OXALIPLATIN (Oxaliplatin)

Snippet

Sponsor: Hospital Universitario Dr. Jose E. Gonzalez | Conditions: Relapsed/Refractory Diffuse Large B Cell Lymphoma | Phase 2 | Status: RECRUITING